Literature DB >> 985048

Platelet monamine oxidase in chronic schizophrenia. Some enzyme characteristics relevant to reduced activity.

D L Murphy, C H Donnelly, L Miller, R J Wyatt.   

Abstract

To evaluate further the basis for the reduced activity of platelet monoamine oxidase (MAO) found in chronic schizophrenic patients, a number of characteristics of the enzyme were compared between patients and controls. Equivalent and statistically significant reductions in activity of the enzyme were found in the patients when tyramine and benzylamine were used as the substrates in comparison to previously reported reductions with tryptamine as the substrate. Michaelis constants for platelet MAO from chronic schizophrenic patients with reduced enzyme activity were not different from controls. Dialysis of the enzyme from patients and controls yielded no changes in activity. Studies of other platelet enzymes, including succinate dehydrogenase, cytochrome C reductase, and lactate dehydrogenase in patients, normal controls, and a subgroup of normal controls with reduced MAO activity, showed no parallel reductions in activity in patients or controls with low MAO activity. These findings suggest that the reduced MAO activity found in chronic schizophrenic patients is apparently not accounted for by nonspecific changes in platelets or platelet mitochondria.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 985048     DOI: 10.1001/archpsyc.1976.01770110105011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  8 in total

1.  Monoamine oxidase activity in different density gradient fractions of human platelets.

Authors:  D L Murphy; J L Costa; B Shafer; L Corash
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

2.  Effect of neurocatin on the activity of monoamine oxidase B in rat brain synaptosomes.

Authors:  S Murphy; A Pastuszko
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

3.  Low platelet monoamine oxidase activity in headache: no correlation with phenolsulphotransferase, succinate dehydrogenase, platelet preparation method or smoking.

Authors:  J Littlewood; V Glover; M Sandler; R Peatfield; R Petty; F Clifford Rose
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-04       Impact factor: 10.154

4.  Platelet monoamine oxidase activity in first-degree relatives of schizophrenic patients.

Authors:  P Propping; W Friedl
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

5.  Inhibition of monoamine oxidases by haloperidol and its metabolites: pharmacological implications for the chemotherapy of schizophrenia.

Authors:  J Fang; P H Yu; J W Gorrod; A A Boulton
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

6.  Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics.

Authors:  J J Mann; R D Kaplan; A Georgotas; E Friedman; M Branchey; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 7.  Human platelet monoamine oxidase activity in health and disease: a review.

Authors:  M Sandler; M A Reveley; V Glover
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

8.  Pathological changes in platelet histamine oxidases in atopic eczema.

Authors:  R Kiehl; G Ionescu
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.